HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

BMS under pressure in schizophrenia; Summit/Akeso on a winning streak

While the large pharma's new drug Cobenfy has stumbled in schizophrenia, it could find new life in Alzheimer's disease

By PharmaVoice · Jun 5, 2026 · via PharmaVoice
BMS under pressure in schizophrenia; Summit/Akeso on a winning streak

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Takeda takes $2.5B legal charge after pay-for-delay verdict, swings to loss for '25
The WeekFiercePharma ↗
Takeda takes $2.5B legal charge after pay-for-delay verdict, swings to loss for '25
The company adjusted its full-year 2025 earnings to account for a legal provision of 402.5 billion JPY ($2.5 b…
Jun 6, 2026
'It looks like this hypothesis will pan out': Cullinan unveils data building case for autoimmune TCEs
The WeekFierceBiotech ↗
'It looks like this hypothesis will pan out': Cullinan unveils data building case for autoimmune TCEs
When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But an…
Jun 6, 2026
Medicare Advantage 2026: Low Premiums, High Limits, Tight Control
The WeekBriefing
Medicare Advantage 2026: Low Premiums, High Limits, Tight Control
Three-quarters of Medicare Advantage enrollees pay no added premium in 2026, but rising out-of-pocket caps and…
Jun 6, 2026